Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Myung Chul | - |
dc.contributor.author | Yoo, Wan Hee | - |
dc.contributor.author | Kang, Seung Baek | - |
dc.contributor.author | Park, Yong-Wook | - |
dc.contributor.author | Kim, Sung Soo | - |
dc.contributor.author | Moon, Kyoung Ho | - |
dc.contributor.author | Song, Yeong Wook | - |
dc.contributor.author | Min, Byung Woo | - |
dc.contributor.author | Cho, Yoon Je | - |
dc.contributor.author | Moon, Seong-Hwan | - |
dc.contributor.author | Bin, Seong-Il | - |
dc.contributor.author | Baek, Han-Joo | - |
dc.contributor.author | Shim, Seung Cheol | - |
dc.contributor.author | Lee, Sung Won | - |
dc.contributor.author | Yoo, Dae Hyun | - |
dc.contributor.author | Mehta, Anish | - |
dc.contributor.author | Skuban, Aleksandar | - |
dc.contributor.author | Cukrow, Diane M. | - |
dc.contributor.author | Vandormael, Kristel | - |
dc.contributor.author | Yan, Li | - |
dc.date.accessioned | 2022-07-16T01:34:08Z | - |
dc.date.available | 2022-07-16T01:34:08Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/158448 | - |
dc.description.abstract | Objective: We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA). Methods: This study included patients (>= 40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100 mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100 mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100 mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10 mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored. Results: There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n = 120) and celecoxib 200 mg (n = 119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were -1.63 mm (-5.37, 2.10), -1.32 mm (-4.88, 2.23), and -1.09 mm (-5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment. Conclusions: Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Dae Hyun | - |
dc.identifier.doi | 10.1185/03007995.2014.955169 | - |
dc.identifier.scopusid | 2-s2.0-84914105208 | - |
dc.identifier.wosid | 000345602300001 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, v.30, no.12, pp.2399 - 2408 | - |
dc.relation.isPartOf | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.title | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.volume | 30 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2399 | - |
dc.citation.endPage | 2408 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | MEDICAL-MANAGEMENT | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | KNEE | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | DICLOFENAC | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | ROFECOXIB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | NAPROXEN | - |
dc.subject.keywordAuthor | Celecoxib | - |
dc.subject.keywordAuthor | COX-2 inhibitor | - |
dc.subject.keywordAuthor | Etoricoxib | - |
dc.subject.keywordAuthor | Korean patients | - |
dc.subject.keywordAuthor | NSAIDs | - |
dc.subject.keywordAuthor | Osteoarthritis | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1185/03007995.2014.955169 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.